LOL at your short pain analogy. But stop, you're getting us excited!
Seriously, tho, the shorts are way too optimistic. Merck's demise is greatly exaggerated. The shorts want blood. They underestimate the power of Merck's cash flow, of the deals it's got in the works with small innovative outfits, of the savvy it will demonstrate in handling the totality of the Vioxx cases. For anyone with cash and guts and a long-term perspective, this the time to buy, while the shorts remain gleeful and hoping for more blood to spill.